Results 251 to 260 of about 6,997,331 (310)
Some of the next articles are maybe not open access.
The safety profile of the fluoroquinolones
Clinical Therapeutics, 2000Premarketing trials showed the fluoroquinolone agents to have a favorable side-effect profile, with treatment-related adverse events comprising gastrointestinal, central nervous system, and dermatologic effects that were generally mild and reversible on cessation of treatment.
J, Bertino, D, Fish
openaire +2 more sources
The Lancet Rheumatology, 2020
BACKGROUND Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2, approved for the treatment of patients with active rheumatoid arthritis.
M. Genovese +12 more
semanticscholar +1 more source
BACKGROUND Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2, approved for the treatment of patients with active rheumatoid arthritis.
M. Genovese +12 more
semanticscholar +1 more source
Safety profile of minimally invasive glaucoma surgery
Current Opinion in Ophthalmology, 2020Purpose of review This article reviews the safety profile of trabecular meshwork/Schlemm's canal-based, subconjunctival, and suprachoroidal minimally invasive glaucoma surgery (MIGS).
K. Vinod, S. Gedde
semanticscholar +1 more source
The American Journal of Cardiology, 2001
Approximately 25% of US adults have high blood pressure (BP). Selection of effective and safe antihypertensive therapy for these individuals is an important health-care priority. High BP can be treated with a wide range of antihypertensive agents from a number of different classes.
openaire +2 more sources
Approximately 25% of US adults have high blood pressure (BP). Selection of effective and safe antihypertensive therapy for these individuals is an important health-care priority. High BP can be treated with a wide range of antihypertensive agents from a number of different classes.
openaire +2 more sources
Clinical Infectious Diseases, 1992
The clinical and laboratory safety of cefprozil was analyzed with data from 4,227 patients who received the drug in North American and European clinical efficacy trials. Of these patients, 3,016 adults and children received capsules or tablets, while 1,211 patients (mostly children) were treated with cefprozil suspension.
R B, Wilber +5 more
openaire +2 more sources
The clinical and laboratory safety of cefprozil was analyzed with data from 4,227 patients who received the drug in North American and European clinical efficacy trials. Of these patients, 3,016 adults and children received capsules or tablets, while 1,211 patients (mostly children) were treated with cefprozil suspension.
R B, Wilber +5 more
openaire +2 more sources
The Pediatric Infectious Disease Journal, 1987
The clinical and laboratory safety of cefixime based on analysis of data from 1575 adults (1118 treated daily and 457 treated twice a day) and 615 children (299 treated daily and 316 treated twice a day) in studies of urinary tract and lower and upper respiratory tract infections (including otitis media) is reviewed.
F P, Tally +3 more
openaire +2 more sources
The clinical and laboratory safety of cefixime based on analysis of data from 1575 adults (1118 treated daily and 457 treated twice a day) and 615 children (299 treated daily and 316 treated twice a day) in studies of urinary tract and lower and upper respiratory tract infections (including otitis media) is reviewed.
F P, Tally +3 more
openaire +2 more sources
Infection, 1992
The results of animal toxicology studies with cefodizime (CDZ) showed no reason for concern with respect to drug safety. Renal tolerance of CDZ proved to be better than that observed with other cephalosporins; furthermore, CDZ had no adverse effects on spermatogenesis, fertility or embryonic development.
openaire +2 more sources
The results of animal toxicology studies with cefodizime (CDZ) showed no reason for concern with respect to drug safety. Renal tolerance of CDZ proved to be better than that observed with other cephalosporins; furthermore, CDZ had no adverse effects on spermatogenesis, fertility or embryonic development.
openaire +2 more sources
Angiology, 1986
Double-blind and long-term open-label studies have demonstrated a remark ably favorable safety profile for bevantolol. The drug was associated with a low incidence of adverse experiences similar to that observed with placebo. The adverse experiences were mostly mild to moderate and of the types found previ ously for other beta-blocking drugs.
openaire +2 more sources
Double-blind and long-term open-label studies have demonstrated a remark ably favorable safety profile for bevantolol. The drug was associated with a low incidence of adverse experiences similar to that observed with placebo. The adverse experiences were mostly mild to moderate and of the types found previ ously for other beta-blocking drugs.
openaire +2 more sources
Safety Profile of Levetiracetam
Epilepsia, 2001Summary: Levetiracetam was approved in November 1999 as add‐on therapy for the treatment of partial‐onset seizures in adults (age 16 years and older). This review focuses on recently published data from four well‐controlled studies in patients with partial‐onset seizures with or without secondary generalization.
openaire +2 more sources
Safety profile of the quinolones
Journal of Antimicrobial Chemotherapy, 1990The most important finding from preclinical evaluation of fluoroquinolones has been their arthropathogenic potential in young animals. This toxic effect is found with all quinolones known so far and has led to the decision not to use them in children and adolescents, despite the fact that the significance of the effect for humans is still unclear.
openaire +2 more sources